Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 5, 2003, Pages 1636-1642

  Hidemura, Kazuhiko ^a   Zhao, Ying Lan ^a,b   Ito, Katsuki ^a   Nakao, Akimasa ^a   Tatsumi, Yasuaki ^a   Kanazawa, Hiroaki ^a   Takagi, Kenzo ^a   Ohta, Michio ^a   Hasegawa, Takaaki ^a,c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SICHUAN UNIVERSITY   (China)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE FLOW; BILIARY EXCRETION; BODY WEIGHT; CONCENTRATION RESPONSE; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; ESCHERICHIA COLI O157; FRACTIONATION; HEPATOBILIARY SYSTEM; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; STEADY STATE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; BILE; BIOLOGICAL TRANSPORT; DOWN-REGULATION; DOXORUBICIN; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; RATS; RATS, WISTAR; SHIGA-LIKE TOXIN II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037997090     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.5.1636-1642.2003     Document Type: Article

References (44)

1. Akita, H., H. Suzuki, and Y. Sugiyama. 2001. Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharm. Res. 18:1119-1125.
2. Andus, T., J. Bauer, and W. Gerok. 1991. Effects of cytokines on the liver. Hepatology 13:364-375.
3. 14C-labelled 4′-epidoxorubicin and doxorubicin in the rat. A comparative study. Cancer Chemother. Pharmacol. 12:157-166.
4. Ballet, F., J. Robert, M. E. Bouma, P. Vrignaud, and R. Infante. 1986. Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture. Pharmacol. Res. Commun. 18:343-347.
5. Barett, T. J., M. E. Potter, and I. K. Wachsmuth. 1989. Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect. Immun. 57:3434-3437.
6. Booth, C. L., K. R. Brouwer, and K. L. Brouwer. 1998. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res. 58:3641-3648.
7. Chen, Y.-L., V. L. Vraux, J.-P. Giroud, and L. Chauvelot-Moachon. 1994. Anti-tumor necrosis factor properties on non-peptide drugs in acute-phase responses. Eur. J. Pharmacol. 271:319-327.
8. Childs, S., R. L. Yeh, E. Georges, and V. Ling. 1995. Identification of a sister gene to P-glycoprotein. Cancer Res. 55:2029-2034.
9. Colombo, T., M. Zucchetti, and M. D'Incalci. 1994. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J. Pharmacol. Exp. Ther. 269:22-27.
10. Cui, Y., J. König, U. Buchholz, H. Spring, I. Leier, and D. Keppler. 1999. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55:929-937.
11. Donner, M. G., and D. Keppler. 2001. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 34:351-359.
12. Evers, R., M. Kool, L. van Deemter, H. Janssen, J. Calafat, L. C. J. M. Oomen, C. C. Paulusma, R. P. J. Oude Elferink, F. Baas, A. H. Schinkel, and P. Borst. 1998. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Investig. 101:1310-1319.
13. Farkas-Himsley, H., R. Hill, B. Rosen, S. Arab, and C. A. Lingwood. 1995. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc. Natl. Acad. Sci. USA 92:6996-7000.
14. - mutant of Shigella dysenteriae 1. Infect. Immun. 56:3099-3109.
15. Gerloff, T., B. Stieger, B. Hagenbuch, J. Madon, L. Landmann, J. Roth, A. F. Hofmann, and P. J. Meier. 1998. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273:10046-10050.
16. Goeptar, A. R., J. M. Te Koppele, E. K. Lamime, J. M. Pique, and N. P. Vermeulen. 1993. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol. Pharmacol. 44:1267-1277.
17. Harel, Y., M. Silva, B. Giroir, A. Weinberg, T. B. Cleary, and B. Beutler. 1993. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by Shiga-like toxin: possible involvement of TNF in hemolytic uremic syndrome. J. Clin. Investig. 92:2110-2116.
18. Hirohashi, T., H. Suzuki, K. Ito, K. Ogawa, K. Kume, T. Shimizu, and Y. Sugiyama. 1998. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Mol. Pharmacol. 53:1068-1075.
19. Karmali, M. A. 1989. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2:15-18.
20. Kaye, S. A., C. B. Louise, B. Boyd, C. A. Lingwood, and T. G. Obrig. 1993. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1β enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect. Immun. 61:3886-3891.
21. Koike, K., T. Kawabe, T. Tanaka, S. Toh, T. Uchiumi, M. Wada, S. Akiyama, M. Ono, and M. Kuwano. 1997. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 57:5475-5479.
22. 6-fold increased cell sensitivity to vetocytotoxin. J. Biol. Chem. 275:6246-6251.
23. Lingwood, C. A., A. A. Khine, and S. Arab. 1998. Globotriaosyl ceramide (Gb3) expression in human turnout cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to verotoxin. Acta Biochim. Pol. 45:351-359.
24. Mariani-Kurkdjian, P., and E. Bingen. 1995. Hemolytic-uremic syndrome after verotoxin-producing Escherichia coli infection. Presse Med. 24:99-101.
25. Nakamura, J., T. Nishida, K. Hayashi, N. Kawada, S. Ueshima, Y. Sugiyama, T. Ito, K. Sobue, and H. Matsuda. 1999. Kupffer cell-mediated down regulation of rat hepatic CMOAT/MRP2 gene expression. Biochem. Biophys. Res. Commun. 255:143-149.
26. Nicolo, G., M. Esposito, A. Belcastro, S. Rovida, E. Margallo, and L. Santi. 1982. Cytophotometric analysis of nuclear uptake of adriamycin in in vivo normal mouse liver and kidney cells. Anal. Quant. Cytol. 4:295-301.
27. O'Brien, A. D., and R. K. Holmes. 1987. Shiga and Shiga-like toxins. Microbiol. Rev. 51:206-220.
28. Ogawa, K., H. Suzuki, T. Hirohashi, T. Ichikawa, P. J. Meier, K. Hirose, T. Akizawa, M. Yoshioka, and Y. Sugiyama. 2000. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol. 278:G438-G446.
29. Paulusma, C. C., P. J. Bosma, G. J. R. Zaman, C. T. M. Bakker, M. Otter, G. L. Scheffer, R. J. Scheper, P. Borst, and R. P. J. Oude Elferink. 1996. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126-1128.
30. Pelletier, H., J. M, Millot, B. Chauffert, M. Manfait, P. Genne, and F. Martin. 1990. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion. Cancer Res. 50:6626-6631.
31. Speeg, K. V., and A. L. Maldonado. 1994. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol. 34:133-136.
32. Speelmans, G., R. W. Staffhorst, B. de Kruijff, and F. A. de Wolf. 1994. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma membrane. Biochemistry 33:13761-13768.
33. Sturm, E., T. L. Zimmerman, A. R. Crawford, S. I, Svetlov, P. Sundaram, J. L. M. Ferrara, S. J. Karpen, and J. M. Crawford. 2000. Endotoxin-stimulated macrophages decrease bile acid uptake in WIF-B cells, a rat hepatoma hybrid cell line. Hepatology 31:124-130.
34. Tavoloni, N., and A. M. Guarino. 1980. Disposition and metabolism of adriamycin in the rat. Pharmacology 21:244-255.
35. Tesh, V. L., and A. D. O'Brien. 1991. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol. Microbiol. 5:1817-1822.
36. Tesh, V. L., J. E. Samuel, L. P. Perera, J. B. Sharefkin, and A. D. O'Brien. 1991. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J. Infect. Dis. 164:344-352.
37. Tesh, V. L., B. Ramegowda, and J. E. Samuel. 1994. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect. Immun, 62:5085-5094.
38. Thiebaut, F., T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. 1987. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738.
39. Van Asperen, J., O. van Tellingen, and J. H. Beijnen. 2000. The role of mdrla P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab. Dispos. 28:264-267.
40. Van Setten, P. A., L. A. Monnens, R. G. Verstraten, L. P. van den Heuvel, and V. W. Hinsbergh. 1996. Effects of verocytotoxin-1 on nonadherent human monocytes. Binding characteristics, protein synthesis, and induction of cytokine release. Blood 88:174-183.
41. Weenen, H., J. M. van Maanen, M. M. de Planque, J. G. McVie, and H. M. Pinedo. 1984. Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicin. Eur. J. Cancer Clin. Oncol. 20:919-926.
42. Zhao, Y. L., X. B. Cen, M. Ito, K. Yokoyama, K. Takagi, K. Kitaichi, M. Nadai, M. Ohta, K. Takagi, and T. Hasegawa. 2002. Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats. Antimicrob. Agents Chemother. 46:1522-1528.
43. Zhao, Y. L., J. Du, H. Kanazawa, X. B. Cen, K. Yokoyama, K. Takagi, K. Kitaichi, Y. Tatsumi, K. Takagi, M. Ohta, and T. Hasegawa. 2002. Shiga-like toxin II modifies brain distribution of a P-glycoprotein substrate, doxorubicin, and P-glycoprotein expression in mice. Brain Res. 956:246-253.
44. Zoja, C., D. Corna, C. Farina, G. Sacchi, C. Lingwood, M. P. Doyle, V. V. Padhye, M. Abbate, and G. Remuzzi. 1992. Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. J. Clin. Med. 120:229-238.